Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Jeez I’m glad we are not discussing doxorubicin 🤣🤣🤣
What a well researched poster.
Cj62
Yep it’s a deal. No more delusional fantastic baseless ramping and I will keep quiet.
Anyhow hopefully next week’s webinar will be unambiguous so won’t be anything to argue about.
Cj62
But that is just the point. To be of use the BB needs to discuss the pros and cons not just be a Pom Pom waving fan club making ridiculous statements about what might happen. Neither should it be viciously abusive.
None of the so-called fudsters make personal attacks in their posts.
Why the realists on here inspire such vitriol escapes me.
I will restate my views for clarity:
1. The platform works
2. Proof of efficacy of AVA6000 needs more trial data
3. Al has said he is taking AVA6000 all the way
4. Deals will be done for AVA3996
5. P2 data will be needed before significant SP movement
So what of the above constitutes “Univested vermin who take pleasure in others misfortune and run avacta to the ground”?
Or are you just going to resort to childish jibes as usual?
#Gracie this one’s for you!
Thompi
Thanks. Didn’t check the Vox interview
Tim
The answer as always is that we don’t know. That is the point of the clinical trials and helps explain why the SP is what it is.
I am not sure Avacta ever stated “ . . . P1a exceeded all expectations“.
Even if they did, what does it mean? The mouse trial results were excellent. I haven’t seen any data that says human trial results weren’t as good. Tumour targeting was expected to be very precise so I don’t see why they were surprised that high dosing would be required in humans before reaching the OMD. Originally we told c5 would be the end. This better all become clear in the AACR presentation.
Derbyone
Give me an example of my daily tripe? Do you mean:
1. Although the platform is proven, AVA6000 efficacy has not been proven in significant numbers.
2. There is still a long way to go before we get a decent dividend
Or is it Pom Pom girl tripe like:
1. Take over next week
2. £10 by Wednesday
3. Hugely impressive data to be published at AACR
Don’t bother to reply. It’s clear which camp you are in.
The saving grace will be if we get more data on more patients including C7 results. But I think all hopes are pinned on arm2 which counteracts speed of dox excretion by dosing every 2 weeks. If that doesn’t show efficacy then there is always weekly dosing which, at the excellent safety AVA6000 has shown, I presume is a possibility.
Yep. Except I think the rich data showing consistently high efficacy across a significant number of patients is what will decide that Avacta is successful.
Get signed up. All our questions will be answered
Wow
Super exciting. The webinar and questions. Will they all be answered
Gje306
Not disputing that but it’s greed at the end of the day. I’ve reached the point where if Avacta delivers on its potential I will have plenty of money so why risk more at this point? All I’m saying. Neither a ramp or deramp. Plenty of people come unstuck by being greedy.
Like some of you, at this time of year I carry out my portfolio annual review which informs my decisions on investing next year’s ISA tranche and perhaps calling time on some old investments.
This year is different because I didn’t invest up to my ISA limit I was waiting to see what would happen with Avacta. So I’ve run out of time and have £15k to invest before end of next week and then another £20k as we go into the new ISA year. Looking back over the last four years it is striking how poorly my investment portfolio has fared and it is all down to Avacta. Not just the drop in SP but also opportunity loss. I would historically expect to have made 12% per year on the money languishing in Avacta.
I have been considering Avacta because at current price it would certainly lower my average. But what is the point? Because if Avacta delivers on its potential I will be very happy with my return on my current investment. If it doesn’t then that’s another £35k down the drain. So this year I am investing elsewhere. It won’t reduce my Avacta average SP cost but it will reduce the proportion of my portfolio at risk in Avacta. And to be honest it will be a “monkey off my back”.
GLA
The Stock Market has surged over last few days. There are better places to put your money to get a return. Simple as that. Not rocket science
If Al went it would be a disaster
The science is not “bulletproof “
Bump
October sounds like a more likely timescale in terms of getting comprehensive trial data published
Benharper
And yet you think that the IIs and BP are as thick as mince for not seeing what you can see even though their combined knowledge eclipses yours and they probably have access to more data than you do.
Energy + CJ
You know I haven’t because there is still a potential huge upside.
The key is getting the dosing regime right so that the huge amount of dox in the AVA6000 has time to be cleaved before excretion of AVA6000 dilutes the levels in the bloodstream. Why can’t you grasp this.
Dosing at current C7 levels if all the available dox was being cleaved into the TME in all cases consistently then the results on the patients would be incredible and the SP would reflect that.